Search results for "EJECTION FRACTION"

showing 10 items of 378 documents

Sacubitril/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction

2020

Background: Heart rate recovery (HRR) is a marker of vagal tone, which is a powerful predictor of mortality in patients with cardiovascular disease. Sacubitril/valsartan (S/V) is a treatment for heart failure with reduced ejection fraction (HFrEF), which impressively impacts cardiovascular outcome. This study aims at evaluating the effects of S/V on HRR and its correlation with cardiopulmonary indexes in HFrEF patients. Methods: Patients with HFrEF admitted to outpatients&rsquo

medicine.medical_specialtyStress testingheart failurelcsh:Medicinecardiopulmonary exercise stress testing030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciencessacubitril/valsartan heart failure heart rate recovery peak oxygen consumption autonomic function cardiopulmonary exercise stress testing0302 clinical medicineInternal medicineHeart ratemedicine030212 general & internal medicinepeak oxygen consumptionheart rate recoveryEjection fractionbusiness.industrylcsh:RGeneral Medicinemedicine.diseaseValsartansacubitril/valsartanHeart failureBreathingCardiologyautonomic functionbusinesshuman activitiesSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

2021

Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients …

medicine.medical_specialtyTranscatheter aorticVentricular Function Leftlaw.inventionTranscatheter Aortic Valve Replacementchemistry.chemical_compoundRandomized controlled trialGlucosideslawInternal medicineDiabetes mellitusmedicineHumansProspective StudiesDapagliflozinBenzhydryl CompoundsHeart FailureEjection fractionbusiness.industryStroke VolumeAortic Valve Stenosismedicine.diseaseStenosisTreatment OutcomechemistryHeart failureAortic ValveCardiologyCardiology and Cardiovascular MedicinebusinessKidney diseaseEuropean journal of heart failureReferences
researchProduct

Six-Month Outcomes of the Tri-Repair Study Assessing the Cardioband Tricuspid Valve Reconstruction System for Patients with Severe Tricuspid Regurgit…

2018

Background: Severe tricuspid regurgitation (TR) is associated with high morbidity and mortality rates with limited treatment options. We report the six-month safety and performance of the Cardioband™ Tricuspid Valve Reconstruction System in the treatment of severe functional TR in 30 patients enrolled in the TRI-REPAIR study. Methods: Between October 2016 and July 2017, 30 patients were enrolled in this single-arm, multicenter, prospective trial. Patients were diagnosed with severe, symptomatic TR in the absence of untreated left-heart disease and deemed inoperable because of unacceptable risk for open-heart surgery by the local heart team. Clinical, functional, and echocardiographic data w…

medicine.medical_specialtyTricuspid valveEjection fractionVena contractabusiness.industryMortality ratemedicine.diseaseClinical trialmedicine.anatomical_structureQuality of lifeInternal medicineHeart failureGood clinical practicemedicinebusinessSSRN Electronic Journal
researchProduct

249 Validation of assessment of circulate oxidative stress markers by the Free Oxygen Radicals Testing (FORT) assay among patients with an acute myoc…

2011

BackgroundFree oxygen radicals play an important role in the pathogenesis of many diseases including cardiovascular diseases, diabetes, cancer and aging. Several methods were developed for the direct or indirect measurement of oxygen free radical and its by-products. Using a new Free Oxygen Radicals Testing (FORT) the current study is designed first to validate the device and to investigate the potential relationships between the ROS and clinical or biological factors in human serum from a population of men with an acute myocardial infarction (AMI).MethodsWe first determined the effect of storage, variability and reproducibility of the FORT test in serum. Then we used the test in 66 patient…

medicine.medical_specialtyUnivariate analysiseducation.field_of_studyEjection fractionbusiness.industryPopulationCancermedicine.disease_causemedicine.diseaseSurgeryPathogenesisDiabetes mellitusInternal medicinemedicineCardiologyMyocardial infarctionCardiology and Cardiovascular MedicinebusinesseducationOxidative stressArchives of Cardiovascular Diseases Supplements
researchProduct

Renal function dynamics following co-administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes

2020

Abstract Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal funct…

medicine.medical_specialtyUrologyRenal function030204 cardiovascular system & hematologySacubitril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHeart failure with reduced ejection fraction (HFrEF)Original Research ArticlesRenal safety profileType 2 diabetes mellitusEmpagliflozinDiseases of the circulatory (Cardiovascular) systemMedicineSGLT2iOriginal Research Article030212 general & internal medicineSacubitril/valsartanCreatinineEjection fractionbusiness.industrymedicine.diseasechemistryValsartanRC666-701Heart failureCardiology and Cardiovascular MedicinebusinessSacubitril Valsartanmedicine.drugRenal function
researchProduct

Right ventricular function and iron deficiency in acute heart failure

2021

Abstract Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was de…

medicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVentricular Function Left03 medical and health sciences0302 clinical medicineLeft ventricle ejection fraction[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineSystoleAgedAged 80 and overHeart FailureIron deficiency.Ejection fractionAnemia Iron-DeficiencybiologyTransferrin saturationbusiness.industryIron deficiencyRight ventricle ejection fractionStroke VolumeGeneral MedicineMiddle AgedPrognosismedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTricuspid annular plane systolic excursionFerritinBlood pressureHeart failureVentricular Function Rightbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct

Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure.

2021

BACKGROUND: Right heart dysfunction (RHD) parameters are increasingly important in heart failure (HF). This study aimed to evaluate the association of advanced RHD with the risk of recurrent admissions across the spectrum of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We included 3383 consecutive patients discharged for acute HF. Of them, in 1435 patients (42.4%), the pulmonary artery systolic pressure could not be measured accurately, leaving a final sample size of 1948 patients. Advanced RHD was defined as the combination of a ratio of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure of less than 0.36 and significant tricuspid regurgitation…

medicine.medical_specialtyVentricular Dysfunction RightHeart failureRegurgitation (circulation)Patient ReadmissionVentricular Function LeftreadmissionsVentricular Dysfunction LeftInterquartile rangemedicine.arteryInternal medicinemedicineHumansHeart FailureEjection fractionbusiness.industryStroke Volumeleft ventricular ejection fractionmedicine.diseasePrognosisBlood pressureSample size determinationHeart failurePulmonary arteryRight heartCardiologyVentricular Function RightCardiology and Cardiovascular Medicinebusinessright heart dysfunction
researchProduct

Involvement of Autonomic Nervous System in New-Onset Atrial Fibrillation during Acute Myocardial Infarction

2020

Background: Atrial fibrillation (AF) is common after acute myocardial infarction (AMI) and associated with in-hospital and long-term mortality. However, the pathophysiology of AF in AMI is poorly understood. Heart rate variability (HRV), measured by Holter-ECG, reflects cardiovascular response to the autonomic nervous system and altered (reduced or enhanced) HRV may have a major role in the onset of AF in AMI patients. Objective: We investigated the relationship between autonomic dysregulation and new-onset AF during AMI. Methods: As part of the RICO survey, all consecutive patients hospitalized for AMI at Dijon (France) university hospital between June 2001 and November 2014 were analyzed …

medicine.medical_specialtyacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAutonomic dysregulationHeart rate variabilityatrial fibrillationMyocardial infarctioncardiovascular diseasesEjection fractionbusiness.industryautonomic nervous systemlcsh:Rheart rate variabilityAtrial fibrillationGeneral Medicinemedicine.diseaseNew onset atrial fibrillationPathophysiologyAutonomic nervous systemCardiologybusiness030217 neurology & neurosurgeryJournal of Clinical Medicine
researchProduct

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine

2021

Heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) constitute two heart failure categories, representing about 50–70% of the total [...]

medicine.medical_specialtyanimal structuresEjection fractionbusiness.industry05 social sciencesRGeneral Medicine030204 cardiovascular system & hematologymedicine.diseasePrecision medicine03 medical and health sciencesEditorialn/a0302 clinical medicineInternal medicineHeart failure0502 economics and businessCardiologymedicineMedicine050211 marketingbusinessHeart failure with preserved ejection fractionJournal of Clinical Medicine
researchProduct

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

2021

BACKGROUND Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet b-blockers are commonly used in HFpEF despite the lack of robust evidence. OBJECTIVES This study aimed to evaluate the effect of b-blocker withdrawal on peak oxygen consumption (peak VO2) in patients with HFpEF and chronotropic incompetence. METHODS This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with b-bloc…

medicine.medical_specialtyanimal structuresEjection fractionpeak Vo2chronotropic incompetencebusiness.industryChronotropic incompetencepercentage of predicted peakVo2Exercise capacitymedicine.diseaseHFpEFCrossover studyHeart failureInternal medicineHeart ratemedicineCardiologyβ-blockersheart ratecrossover trialCardiology and Cardiovascular MedicinePeak vo2Heart failure with preserved ejection fractionbusiness
researchProduct